Dongwha Pharm-MSD Korea signs license agreement of antidepressant ‘Remeron’

Dongwha Pharm(CEO Ji-Hoon Sohn) signed a MSD’s exclusive sale and supply agreement of Remeron(generic name: mirtazapine), a MSD’s antidepressant, in Korea on the 8^th of September.

Remeron, a MSD’s NaSSA(antidepressant with the Noradrenergic and Specific Serotonergic Antidepressants) mechanism, was developed in 1996, acquired approvals from both of the U.S. FDA and the EMA(European Medicines Ag...